Leukemia Therapeutics Market Report 2026

The leukemia therapeutics market size has grown strongly in recent years. It will grow from $18.67 billion in 2025 to $20.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising leukemia incidence rates, development of first-generation chemotherapy drugs, increased healthcare expenditure in developed regions, advancements in bone marrow transplantation, growth in biologics research.

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $27.41 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to expansion of CAR T-cell therapies, adoption of precision medicine approaches, integration of AI in treatment planning, growth in homecare treatment solutions, development of novel targeted therapies. Major trends in the forecast period include personalized leukemia treatment, advanced diagnostic integration, outpatient and home-based therapy expansion, combination therapy development, rare and resistant leukemia focus.

The increasing prevalence of leukemia is contributing to the growth of the leukemia therapeutics market. Leukemia is a form of blood cancer that originates in the bone marrow and leads to uncontrolled production of abnormal blood cells. Improved access to medical care for leukemia patients worldwide, along with the expanding availability of treatment options, has increased the demand for leukemia therapies. For example, in January 2023, the American Cancer Society, a US-based health organization, reported that approximately 59,610 new cases of leukemia of all types and about 23,710 deaths related to leukemia were expected in the United States in 2023. In addition, an estimated 20,380 new cases of acute myeloid leukemia (AML) and around 11,310 deaths associated with AML were projected for the same year. As a result, the rising incidence of leukemia is supporting the growth of the leukemia therapeutics market.

Major companies operating in the leukemia therapeutics market are focusing on the development of innovative treatments, such as CAR T-cell therapies, to expand their customer base, boost sales, and increase revenue. Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy used to treat certain types of cancer. For example, in March 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved Breyanzi (lisocabtagene maraleucel; liso-cel). This therapy is a CD19-directed CAR T-cell treatment intended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma-2 (BCL-2) inhibitor.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition strengthens AstraZeneca’s growing cell therapy pipeline through the addition of GC012F, a novel clinical-stage FasTCAR-enabled autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets both BCMA and CD19. Following the acquisition, Gracell will operate as a wholly owned subsidiary of AstraZeneca, continuing its activities in both China and the United States. Gracell Biotechnologies Inc. is a China-based biopharmaceutical company focused on the development of cell therapies for leukemia and autoimmune disorders.

Major companies operating in the leukemia therapeutics market are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

North America was the largest region in the leukemia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the leukemia therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs), laboratory equipment, and biologics production materials. This impact is most significant in regions reliant on international supply chains, such as Asia-Pacific and parts of Europe. Segments like targeted therapy, biologics, and CAR T-cell therapy are particularly affected due to the high-cost components. While tariffs may increase production costs, they also encourage local manufacturing and innovation, leading to potential self-reliance and development of cost-optimized treatment solutions.

The leukemia therapeutics market research report is one of a series of new reports that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry. This leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leukemia therapeutics refer to treatments used to manage an aggressive, rapidly progressing cancer in which the blood or bone marrow contains an excessive number of myeloblasts, or immature white blood cells. The choice of treatment for leukemia depends on several factors, including the patient’s age, overall health, the specific type of leukemia, its stage, and its location within the body.

The primary treatment approaches in leukemia therapeutics include chemotherapy, immunotherapy, targeted therapy, and other treatment options. Immunotherapy is a treatment strategy that enhances the body’s immune system to identify and destroy cancerous cells. These therapies are used to treat acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and other forms of leukemia, utilizing both small-molecule drugs and biologics. Leukemia therapeutics are administered across various end-user settings, including hospitals, homecare environments, specialty clinics, and other healthcare facilities.

The leukemia therapeutics market includes revenues earned by entities by killing fast-growing cancer cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.